14.32
-0.12(-0.83%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
1089
First IPO Date
March 23, 2020
| Name | Title | Pay | Year Born |
| Dr. Jisong Cui Ph.D. | Co-Founder, Chairwoman & Chief Executive Officer | 9.34M | 1963 |
| Dr. Renbin Zhao Ph.D. | Senior Vice President of Clinical Development & Medical Research and Executive Director | 3.74M | 1969 |
| Dr. Xiangyang Chen Ph.D. | Chief Technology Officer | 0 | 1967 |
| Yue Tan | Accounting Supervisor | 0 | N/A |
| Mr. Nan Gao | Chief Operating Officer | 0 | 1974 |
| Mr. Jeff Chen | Chief Commercial Officer | 0 | N/A |
| Mr. Xin Fu | Chief Financial Officer | 0 | 1978 |
| Mr. Davy Ouyang Ph.D. | Vice President & Head of Biology | 0 | N/A |
| Ms. Junsu Wang | General Counsel | 0 | 1977 |
| Junjian Liu Ph.D. | Senior Vice President of Biology & Biologics | 0 | N/A |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.